NGM Biopharmaceuticals Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of NGM Biopharmaceuticals Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 16 Apr 2019 | Lorem |
| CymaBay’s Phase II seladelpar NASH trial prospects foggy due to uncertain PPAR delta target value, experts say | 23 Nov 2018 | Reynald Castaneda |
| Enanta’s Phase II FXR agonist trial has poor clinical value for efficacy in NASH; Phase I data, structural difference limited success indicator, experts say | 22 Nov 2018 | Reynald Castaneda |
| Dimerix could start CRO search for Phase Ib or II NASH trial in 2H16 – exec | 13 Jun 2016 | Reynald Castaneda |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer